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Objectives: Direct-acting antivirals containing nonstructural protein 5A (NS5A) inhibitors administered over 8 to 12 weeks are
effective inw95% of patients with hepatitis C virus. Nevertheless, patients resistant to NS5A inhibitors have lower cure rates
over 8 weeks (,85%); for these patients, 12 weeks of treatment produces cure rates greater than 95%. We evaluated the
lifetime cost-effectiveness of testing for NS5A resistance at baseline and optimizing treatment duration accordingly in
genotype 1 noncirrhotic treatment-naïve patients from the perspective of the UK National Health Service.
Methods: A decision-analytic model compared (1) standard 12-week treatment (no testing), (2) shortened 8-week treatment
(no testing), and (3) baseline testing with 12-/8-week treatment for those with/without NS5A polymorphisms. Patients who
failed first-line therapy were retreated for 12 weeks. Model inputs were derived from published studies. Costs, quality-
adjusted life-years, and the probability of cost-effectiveness were calculated.
Results: Baseline testing had an incremental net monetary benefit (INMB) of £11 838 versus standard 12 weeks of therapy (no
testing) and low probability (31%) of being the most cost-effective, assuming £30 000 willingness to pay. Shortened 8 weeks
of treatment (no testing) had an INMB of £12 294 and the highest probability (69%) of being most cost-effective. Scenario
analyses showed baseline testing generally had the highest INMB and probability of being most cost-effective if first- and
second-line drug prices were low (,£20k).
Conclusions: Optimizing treatment duration based on NS5A polymorphisms for genotype 1 noncirrhotic treatment-naive
patients in the United Kingdom is not cost-effective if the drug costs are high; the strategy is generally most cost-effective
when drug prices are low (,£20k).
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The burden and prevalence of hepatitis C virus (HCV) world-
wide remains high, with more than 70 million people, or 1% of the
world’s population, currently living with the chronic infection.1
The World Health Organization recently committed to reducing
the number of new HCV cases and deaths worldwide by 2030.2
Efforts to reduce the burden of HCV have been invigorated by
the advent of direct-acting antivirals (DAAs), which produce high
cure rates (w95%) over relatively short courses of treatment (8-12
weeks) and offer good side-effect profiles.3 Nevertheless, there is
emerging evidence that, for selected patients, treatment over the
licensed duration of therapy can be unnecessary or less effective.ss correspondence to: Christopher G. Fawsitt, PhD, Bristol Medical School,
.fawsitt@bristol.ac.uk
15 - see front matter Copyright ª 2019, ISPOR–The Professional Society for
cess article under the CC BY license (http://creativecommons.org/licenses/b
doi.org/10.1016/j.jval.2019.08.012DAA regimens containing nonstructural protein 5A (NS5A) in-
hibitor can be less effective in patients with NS5A polymorphisms
or resistance-associated substitutions (RASs). One widely used
combination therapy, ledipasvir/sofosbuvir (LDV/SOF), for
example, produces high and relatively comparable cure rates or
sustained virological response (SVR, effective cure) over a stan-
dard 12-week treatment duration (96.3%)4 as a shortened 8-week
treatment duration (94.6%) in genotype 1 (GT1) noncirrhotic
treatment-naïve (TN) patients.5 Nevertheless, in NS5A inhibitor-
resistant patients, a significantly lower SVR has been observed
over an 8-week treatment duration (82.8%) than over a 12-week
treatment duration (95.7%).5 Outcomes for this group could be
considerably improved if the patient’s resistance profile wasUniversity of Bristol, 1-5 Whiteladies Rd, BS8 1NU, England, United Kingdom.
Health Economics and Outcomes Research. Published by Elsevier Inc. This is an
y/4.0/).
ECONOMIC EVALUATION 181determined at baseline using single-gene sequencing, or resis-
tance testing, and treatment duration optimized accordingly.
Despite the clinical benefits resistance testing can provide, it is
not widely used. In some circumstances, resistance testing is
recommended routinely when optimizing treatment for an indi-
vidual patient. For one combination therapy, elbasvir/grazoprevir
(ELB/GZR), resistance testing is recommended to guide the dura-
tion of therapy.6 In patients with NS5A polymorphisms, a 16-week
treatment duration is recommended, whereas a standard 12-week
treatment duration is recommended for patients without the
RASs. The cost-effectiveness of resistance testing has also been
documented in the literature.7,8 Westerhout et al8 considered the
cost-effectiveness of testing for NS5A polymorphisms at baseline
in GT1 treatment-experienced patients with severe or compen-
sated cirrhosis in Italy. Patients were treated for 12 weeks if they
had severe cirrhosis and NS5A polymorphisms at baseline and 24
weeks if they had compensated cirrhosis and NS5A poly-
morphisms at baseline. The authors found baseline testing was
cost-effective versus no testing (with nonstratified treatment
durations of 12 or 24 weeks for patients with severe or compen-
sated cirrhosis, respectively).8 In the United States, Elbasha and
colleagues7 considered the cost-effectiveness of baseline testing in
GT1a TN and treatment-experienced patients. Nevertheless, the
authors treated patients for 12 weeks if no NS5A RASs were pre-
sent at baseline and 16 weeks otherwise. The authors similarly
found the results favored baseline testing versus no testing in
noncirrhotic TN patients.7 No study has yet considered the cost-
effectiveness of baseline testing in the context of shorter treat-
ment durations, which have been shown to be highly clinically
effective5,9 and cost-effective10 in GT1 noncirrhotic TN patients.
Adjusting the treatment duration based on the presence of
NS5A polymorphisms carries the potential to increase the rate of
successful outcomes in patients through increased cure rates,
thereby limiting the incidence of liver-related morbidity and
mortality and associated healthcare costs. Nevertheless, baseline
testing introduces additional costs that must be considered in the
context of its potential benefit. In this article, we investigate the
lifetime cost-effectiveness of testing for resistance to NS5A
inhibitor-containing regimens at baseline in GT1 noncirrhotic TN
patients in the United Kingdom, with treatment duration opti-
mized to 12 weeks in NS5A-resistant patients and 8 weeks
otherwise. We compared baseline testing against a standard 12-
week treatment duration for all patients, which is the generally
recommended treatment duration. An additional strategy of a
shortened 8-week treatment duration for all patients was also
considered because this strategy is sometimes recommended,
particularly for newer regimens,11 and it may offer cost advantages
beyond baseline testing that need to be considered.Methods
We adapted a previously validated decision tree and Markov
model10 to assess the cost-effectiveness of baseline testing for
NS5A polymorphisms from the perspective of the UK National
Health Service (NHS). We assumed monthly cycles in the decision
tree to simulate treatment outcomes in the first year and annual
cycles in the Markov model to simulate the natural disease history
of HCV. We adopted a lifetime time horizon, projecting outcomes
over 60 years, and discounted future costs and benefits at 3.5% per
annum, in line with UK guidance.12
Patient Population
We modeled outcomes for HCV GT1 (subtypes 1a and 1b
combined) noncirrhotic TN patients in the United Kingdom. Weconsidered outcomes for patients with mild (F0-F1) and moderate
(F2-F3) liver fibrosis, as informed by UK data13 (Table 1). Patients
were aged 40 years, and 70% were male at model entry.13
Treatment Strategies
We compared the following strategies:
 NoTest12wks: standard 12-week treatment duration (with no
testing)
 NoTest8wks: shortened 8-week treatment duration (with no
testing)
 Test12/8wks: baseline testing with 12-week treatment duration
if NS5A resistant, 8 weeks otherwise
For the purposes of this analysis, we assumed NoTest12wks as
the reference strategy because this is the standard recommended
treatment duration in the United Kingdom. Under each strategy,
we assumed that patients who failed first-line treatment were
retreated for 12 weeks, as per recent UK guidelines.24,25
We assumed LDV/SOF as first-line therapy because it may be
recommended for use over 8 to 12 weeks in GT1 noncirrhotic TN
patients, so there is considerable evidence available on the effec-
tiveness of the regimen in the studied population over the
different treatment durations. LDV/SOF is an NS5A inhibitor-
containing regimen that is administered daily using a fixed-dose
tablet; each tablet contains 90 mg LDV (NS5A inhibitor) and 400
mg SOF (polymerase inhibitor).4 We assumed sofosbuvir/velpa-
tasvir/voxilaprevir (SOF/VEL/VOX) as second-line therapy (ie,
retreatment regimen) because it is the currently recommended
treatment regimen in patients who previously failed first-line
therapy in the United Kingdom.24 SOF/VEL/VOX is also an NS5A
inhibitor-containing regimen that is administered once daily using
a fixed-dose tablet; each tablet contains 400 mg SOF, 100 mg VEL
(NS5A inhibitor), and 100 mg VOX (protease inhibitor).21
Model Structure
We used a decision tree and Markov model (see Appendix 1 in
the Supplemental Materials found at https://doi.org/10.1016/j.
jval.2019.08.012) to assess treatment and lifetime outcomes,
respectively. Patients were treated for either 12 or 8 weeks,
depending on the strategy, and they were assessed 12 weeks after
end of treatment for an effective cure (SVR12). SVR12 was defined
as having HCV ribonucleic acid (RNA) less than 25 IU/mL. A 12-
week salvage regimen was administered at 24 weeks during the
decision tree if patients failed first-line therapy.
A Markov model was used to reflect long-term outcomes
beyond the decision tree. All patients entered the model based on
their response to treatment (SVR or fail) and initial liver fibrosis
(mild or moderate). HCV-cleared patients could become reinfected
at any point during the model, whereas HCV-infected patients
could progress to more advanced stages of liver disease, including
compensated cirrhosis, decompensated cirrhosis, and hepatocel-
lular carcinoma. Patients in these advanced health states were at
risk of requiring a liver transplant. The model captured the varying
risk of liver-related mortality in these advanced health states, with
additional health states included in the hepatocellular carcinoma
and liver transplant health states to reflect the initial and subse-
quent risk of mortality. The model also captured the risk of all-
cause mortality.
Model Assumptions
During treatment, we assumed patients could not progress to
more advanced stages of liver disease. Patients who failed first-
line treatment were retreated at 24 weeks during the decision
Table 1. Summary of treatment, epidemiological, cost, and quality-of-life inputs for probabilistic sensitivity analyses.
Variable Base case Distribution Alpha* Beta* Source
Patient characteristics
Initial distribution of liver fibrosis
Mild (F0-F1) 51.1% — — — 13
Moderate (F2-F3) 48.9% — — — 13
Age 40 — — — 13
Male 70% — — — 13
Efficacy (SVR12)
First-line treatment: LDV/SOF
NoTest12wks 0.963 Beta 208 8 4
NoTest8wks 0.946 Beta 209 12 5
Test12/8wks
NS5A (12 weeks) 0.957 Beta 45 2 5
No NS5A (8 weeks) 0.964 Beta 185 7 5
Retreatment – SOF/VEL/VOX
NoTest12wks//NoTest8wks 0.973 Beta 142 4 14
NS5A (Test12/8wks) 0.968 Beta 120 4 14
No NS5A (Test12/8wks) 0.977 Beta 42 1 14
Resistance prevalence
NS5A 0.115 Beta 102 785 5
Annual transition probabilities
Fibrosis progression
Mild-to-moderate 0.025 Beta 38 1484 15,16
Moderate-to-CC 0.037 Beta 27 699 15, 16
Nonfibrosis progression
CC-to-DCC 0.039 Beta 15 359 17
CC-to-HCC 0.014 Beta 2 135 18
DCC-to-HCC 0.014 Beta 2 135 18
HCC-to-liver transplant 0.020 Beta 98 4801 13
DCC-to-liver transplant 0.020 Beta 98 4801 15
Liver-related mortality
DCC-to-liver death 0.130 Beta 147 983 17
HCC-to-liver death (first year) 0.430 Beta 117 155 17
HCC-to-liver death (subsequent year) 0.430 Beta 117 155 17
Liver transplant-to-liver death (first
year)
0.150 Beta 85 481 15
Liver transplant-to-liver death
(subsequent year)
0.057 Beta 85 1407 19
Reinfection 0.010 Beta 4 391 20
Costs
Resistance test costs
Single-gene sequencing £100.00 Fixed — — Assumption
Treatment-related costs
LDV/SOF (monthly) £13 225.20 Fixed — — 4
SOF/VEL/VOX (monthly) £14 942.33 Fixed — — 21
Monitoring costs (monthly) £162.34 Fixed — — 4
Health state costs
SVR mild (F0-F1) £60.36 Gamma 34 2 21
SVR moderate (F2-F3) £60.36 Gamma 34 2 21
Mild (F0-F1) £166.50 Gamma 13 13 13
Moderate (F2-F3) £612.50 Gamma 35 17 21
CC (F4) £951.13 Gamma 17 54 21
DCC £12 833.96 Gamma 15 849 13
HCC (first year) £11 436.41 Gamma 13 894 13
HCC (subsequent year) £11 436.41 Gamma 13 894 13
Liver transplant (first year) £51 769.79 Gamma 15 3473 13
Liver transplant (subsequent year) £1949.08 Gamma 14 136 13
Adverse event costs
Anemia £501.58 Gamma 10 48 20
Rash £166.50 Gamma 16 10 20
Depression £414.17 Gamma 16 26 20
Neutropenia £980.26 Gamma 10 98 20
Thrombocytopenia £875.16 Gamma 14 62 20
continued on next page
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Table 1. Continued
Variable Base case Distribution Alpha* Beta* Source
Utilities
Treatment-related utilities (penalties)
Mild (F0-F1) (monthly) –0.002 Beta 72 39 466 23
Moderate (F2-F3) (monthly) –0.002 Beta 72 39 466 23
Health state utilities
SVR mild (F0-F1) 0.820 Fixed — — 16
SVR moderate (F2-F3) 0.710 Fixed — — 16
Mild (F0-F1) 0.770 Beta 141 42 16
Moderate (F2-F3) 0.660 Log-normal — — 16
CC (F4) 0.550 Log-normal — — 16
DCC 0.450 Beta 55 67 16
HCC (first year) 0.450 Beta 55 67 16
HCC (subsequent year) 0.450 Beta 55 67 16
Liver transplant (first year) 0.450 Beta 55 67 13
Liver transplant (subsequent year) 0.670 Beta 32 16 16
CC indicates compensated cirrhosis; DCC, decompensated cirrhosis; HCC, hepatocellular carcinoma; LDV/SOF, ledipasvir/sofosbuvir; SOF/VEL/VOX, sofosbuvir/
velpatasvir/voxilaprevir; SVR12, sustained virological response at 12 weeks. NoTest12wks, standard 12-week treatment duration (with no testing); NoTest8wks,
shortened 8-week treatment duration (with no testing); Test12/8wks, baseline testing with 12-week treatment duration if NS5A resistant, 8 weeks otherwise.
*Parameters of a beta distribution describing uncertainty in probability parameters.
ECONOMIC EVALUATION 183tree. There are no guidelines on when a salvage treatment should
be administered, and it is unclear whether the timing of retreat-
ment affects patients’ chance of viral eradication. In our model, we
assumed the timing did not affect retreatment success. Although
HCV-cleared patients could become reinfected, to be conservative
we assumed these patients were not treated again and progressed
through the model. We applied drug costs on a per-tablet basis
(estimated monthly), rather than a per-treatment success/failure
basis.Parameter Inputs
Model inputs are presented in Table 1 and described below.
Treatment-Related Inputs
The primary source of evidence on NS5A prevalence and first-
line treatment efficacy was derived from Sarrazin et al,5 who
recently synthesized evidence from phase II and III clinical trials in
Europe and the United States. The authors reported outcomes for
2144 patients who had been treated over 12 or 8 weeks using LDV/
SOF. At baseline, 11.5% of GT1 noncirrhotic TN patients had at least
1 RAS that conferred more than 100-fold resistance to NS5A in-
hibitor using a 1% cutoff value for deep sequencing (Table 1). The
RASs included Q30H, Q30G, Q30R, L31I, L31M, L31V, P32L, M28A,
M28G, Q30E, Q30K, H58D, Y93C, Y93H, Y93N, and Y93S in GT1a
and P58D, A92K, and Y93Hin GT1b. Overall, 94.6% of patients
(including both those with and without NS5A polymorphisms)
achieved SVR12 over 8 weeks. Patients with NS5A resistance at
baseline had similar SVR12 over 12 weeks at 95.7% as patients
without the RAS treated for 8 weeks at 96.4%. We used these
prevalence and efficacy data and assumed beta distributions for
NoTest8wks and Test12/8wks, with uncertainty around these esti-
mates given in Table 1. In the United Kingdom, SVR12 in patients
treated for a standard 12-week treatment duration using the same
regimen is 96.3%.4 We used this efficacy source and assumed a
beta distribution for NoTest12wks, with uncertainty in this
parameter also described in Table 1.
Bourliere and colleagues14 provided evidence on the efficacy of
retreatment using SOF/VEL/VOX over 12 weeks from two phase III
clinical trials (POLARIS-1 and POLARIS-4). Overall, 97.3% of pa-
tients (142 of 146) achieved SVR12; this informed betadistributions on SVR12 in patients who failed either the
NoTest12wks or NoTest8wks strategy. In patients with and without
NS5A polymorphisms at baseline, 96.8% (120 of 124) and 97.7% (42
of 43) achieved SVR12, respectively; we used these data to inform
beta distributions on SVR12 for Test12/8wks (Table 1).
We modeled the probability that treatment-related adverse
events occur to reflect the potential impact of clinical events over
different treatment durations. We used data from earlier work,10
which in turn was derived from Johnson and colleagues.20 We
estimated the probability of adverse events over 12 and 8 weeks,
respectively.10 Although these events were observed for an alter-
native DAA, we assumed the probabilities were comparable
because side effect profiles are generally good across DAAs and
occur uniformly.26 We applied the same probabilities for retreat-
ment as first-line treatment. The events included anemia, rash,
depression, grade 3 or 4 neutropenia, and grades 3 or 4
thrombocytopenia.
Epidemiological Inputs
The natural disease history of HCV was modeled using the
Markov model and annual transition probabilities, which are
presented in Table 1. The parameter estimates were taken from
published studies on the probability of reinfection (1% per
annum),20 fibrosis15,16 and nonfibrosis17,18 progression, liver-
related mortality,15,17,19 and all-cause mortality, stratified by age
and sex.27
Costs
The model considered treatment-related and health state costs
from the perspective of the UK NHS (Table 1). Treatment-related
costs included resistance test costs, drug costs, monitoring
costs,4 and adverse event costs.20 We assumed that the cost of a
resistance test (single-gene sequencing) was £100 in the base case
analysis. The cost of first-line treatment and retreatment was
derived from the UK technology appraisals for LDV/SOF4 and SOF/
VEL/VOX,21 respectively. We assumed resistance test costs, drug
costs, and monitoring costs were fixed in the model; these were
not expected to vary in the UK. Health state costs were derived
from published studies in the United Kingdom.13,22 We valued
costs at 2017-2018 prices, expressed in Sterling (£), and inflated
184 VALUE IN HEALTH FEBRUARY 2020any outdated prices to current prices.28 A gamma distribution was
assumed for all nonfixed cost inputs.
Utilities and quality-adjusted life-years
We used quality-adjusted life-years (QALYs) as our measure of
health benefit and calculated these using published utility esti-
mates.16,23 Treatment-related utilities, which reflect the deterio-
ration in quality of life owing to adverse events, were derived from
Chahal and colleagues23 for first-line treatment (Table 1). We
assumed the same utility penalties for retreatment as there were
no published estimates available for the new salvage regimen
(SOF/VEL/VOX) at the time of writing. Health state utilities were
derived from Wright and colleagues.16 We assumed HCV-cleared
patients had a higher utility than HCV-infected patients by a
score of 0.05, consistent with previous analyses.13,20 We set this
utility as fixed in the model and assumed beta distributions for all
other utility parameters (Table 1).
Cost-Effectiveness Analyses
Base-case analysis
We compared the lifetime cost-effectiveness of Test12/8wks
and NoTest8wks against NoTest12wks for GT1 noncirrhotic TN pa-
tients in the United Kingdom. We calculated the expected lifetime
costs and QALYs per 1000 patients using probabilistic sensitivity
analysis. We performed 10 000 Monte Carlo simulations, with
point estimates randomly sampled from predefined probability
distributions, using Microsoft Excel software (Redmond, WA). We
report the expected net monetary benefit (NMB), and relative to
NoTest12wks, we calculated the expected incremental net mone-
tary benefit (INMB) and 95% credible intervals (CrIs) using
willingness-to-pay thresholds of £20 000 and £30 000. The
optimal strategy at a given willingness-to-pay threshold is the
strategy with the highest expected INMB (or equivalently ex-
pected NMB). We explored uncertainty in the optimal strategy by
reporting the probability that each strategy was the most cost-
effective strategy in a cost-effectiveness acceptability curve
(CEAC), and the probability that the optimal strategy was the most
cost-effective in a cost-effectiveness acceptability frontier (CEAF),
both plotted across a range of different willingness-to-pay
thresholds. We also reported the number of liver-related events
(ie, decompensated cirrhosis, hepatocellular carcinoma, liver
transplant) in each strategy and calculated the number of events
avoided in the NoTest8wks and Test12/8wks strategies relative to
NoTest12wks.
Sensitivity and scenario analyses
The prices paid for DAA regimens are not published. To take
account of lower prices negotiated as part of large-volume deals,
we investigated a price reduction to the DAA regimens of 80%,
which lowered the cost of first-line treatment (LDV/SOF) and
retreatment (SOF/VEL/VOX) to £7935 and £8965 per patient over
12 weeks, respectively. We assumed this overall reduction to allow
for differences in the cost of first- and second-line therapy, as SOF/
VEL/VOX was expected to cost more than LDV/SOF.
Assuming the same 80% reduction in drug costs, we conducted
a range of other sensitivity and scenario analyses. We undertook a
1-way deterministic sensitivity analysis of NoTest8wks and Test12/
8wks relative to NoTest12wks, respectively, to investigate how
sensitive the results were to fluctuations in parameter values.
Where we had limited data on parameters, such as the cost of
first- and second-line treatment, we assessed uncertainty using
620%. We further investigated the sensitivity to lower and higher
resistance test costs (single-gene sequencing) by varying the cost
of the resistance test between £50 and £250. We investigated thesensitivity to the SVR12 after first-line treatment in NS5A-
resistant patients treated for 12 weeks to determine the SVR12
threshold that would be required to ensure Test12/8wks is cost-
effective. As there is no established evidence on the improve-
ment in quality of life of patients with mild/moderate liver fibrosis
after SVR, we assessed the sensitivity to this assumption by
removing the utility increase (of 0.05) and assuming the same
utilities for HCV-cleared and -infected patients.
Finally, we conducted a 2-way probabilistic sensitivity analysis
on first-line treatment and retreatment drug prices to further
explore the issue of drug costs and determine the most cost-
effective strategy for a complete range of price combinations.
Here, we considered differential percentage reductions in the cost
of first- and second-line treatment.Results
Base-Case Findings
Compared with NoTest12wks, Test12/8wks generated lower
expected lifetime costs due to reduced treatment costs in nonre-
sistant patients and higher expected QALY gains due to more
favorable first- and second-line cure rates in nonresistant patients
treated for 8 weeks (Table 2). These patients were also exposed to
the disutility of treatment for a shorter period of time versus
NoTest12wks. Nevertheless, NoTest8wks had the lowest expected
lifetime costs due to lower treatment costs overall and higher
QALY gains versus NoTest12wks due to the shortened exposure to
the side effects of treatment. At £20 000 willingness-to-pay,
NoTest8wks had an INMB of £12 289 (95% CrI £10 439-£14 100)
and 74% probability of being the most cost-effective option;
Test12/8wks had a lower INMB at £11 700 (95% CrI £10 439-£13
334) and only 26% probability of being the most cost-effective
strategy. At £30 000 willingness-to-pay, the probability that
Test12/8wks was the most cost-effective strategy was marginally
higher, at 31%. At both willingness-to-pay thresholds, NoTest8wks
was the optimal strategy with the highest expected INMB, and this
finding was associated with a high level of certainty, as shown in
the CEAC and CEAF (Appendix 3).
The number of liver-related events was relatively comparable
across each strategy (Appendix 2). Test12/8wks had fewer cases of
hepatocellular carcinoma, decompensated cirrhosis, and liver
transplant than NoTest12wks, whereas NoTest8wks had slightly
more; however, there was limited evidence to suggest the number
of clinical events differed meaningfully across the strategies.
Sensitivity/Scenario Analyses Findings
When drug prices were reduced by 80%, Test12/8wks became
more cost-effective at £30 000 willingness-to-pay, as the small
improvement in QALY gains was cost-effective at the lower drug
tariff and higher cost-effectiveness threshold (Table 2). Test12/
8wks had an expected INMB of £2782 (95% CrI £2307-£3240) and
67% probability of being the most cost-effective strategy;
NoTest8wks had an INMB of £2671 (95% CrI £2163-£3157) and 33%
probability of being the most cost-effective strategy. At the lower
cost-effectiveness threshold of £20 000, NoTest8wks had the
highest probability of being most cost-effective (55%), although
there was more uncertainty around the optimal strategy (see CEAC
and CEAF in Appendix 3).
Figures 1 and 2 present the top 10 varied parameters of the 1-
way sensitivity analysis of NoTest8wks and NoTest12/8wks versus
NoTest12wks, respectively; the full complement of results is
presented in Appendix 4. Both strategies remained cost-effective
when parameters were held at their upper/lower bounds. The
Table 2. Cost-effectiveness findings.
Costs QALYs £20 000 WTP £30 000 WTP
e(NMB)* e(INMB)* P(CE) e(NMB)* e(INMB)* P(CE)
(95% CrI) (95% CrI) (95% CrI) (95% CrI)
Base-case analysis
NoTest12wks £43 976
(£42 150-
£46 470)
15.515
(15.011-
16.167)
£266 319
(£254 664-
£280 379)
— .00 £421 467
(£404 872-
£442 028)
— .00
NoTest8wks £31 698
(£29 744-
£34 227)
15.515
(15.01-
16.167)
£278 608
(£266 905-
£292 679)
£12 289
(£10 439-
£14 100)
.74 £433 761
(£417 198-
£454 346)
£12 294
(£10 411-
£14 142)
.69
Test12/8wks £32 552
(£30 731-
£34 982)
15.529
(15.021-
16.182)
£278 019
(£266 301-
£292 130)
£11 700
(£10 074-
£13 334)
.26 £433 305
(£416 594-
£453 941)
£11 838
(£10 183-
£13 505)
.31
Sensitivity analysis (80% reduction in drug prices)
NoTest12wks £12 053
(£10 591-
£14 268)
15.510
(15.008-
16.165)
£298 150
(£286 460-
£312 194)
— .00 £453 252
(£436 581-
£473 817)
— .00
NoTest8wks £9399
(£7946-
£11 612)
15.511
(15.009-
16.166)
£300 815
(£289 139-
£314 856)
£2665
(£2194-
£3116)
.55 £455 923
(£439 265-
£476 535)
£2671
(£2163-
£3157)
.33
Test12/8wks £9683
(£8242-
£11 851)
15.524
(15.018-
16.181)
£300 795
(£289 020-
£314 850)
£2645
(£2224-
£3064)
.45 £456 034
(£439 299-
£476 640)
£2782
(£2307-
£3240)
.67
CrI indicates credible interval; e(INMB), expected incremental net monetary benefit; P(CE), probability most cost-effective; QALYs, quality-adjusted life years; WTP,
willingness-to-pay. NoTest12wks, standard 12-week treatment duration (with no testing); NoTest8wks, shortened 8-week treatment duration (with no testing); Test12/
8wks, baseline testing with 12-week treatment duration if NS5A resistant, 8 weeks otherwise.
*Versus NoTest12wks.
ECONOMIC EVALUATION 185key drivers of cost-effectiveness were the cost and efficacy of
first-line treatment. Lower first-line treatment costs reduced the
expected INMB of both strategies relative to NoTest12wks
because of the reduced cost-savings overall. The INMB of
NoTest8wks and Test12/8wks increased when SVR, after first-line
treatment, was held at its upper value (97.2% and 98.5% in
nonresistant patients treated for 8 weeks, respectively). The
cost-effectiveness of both strategies also increased when SVR in
the NoTest12wks strategy was held at its lower value (93.3%). Few
other inputs had an effect on the INMB of NoTest8wks and
NoTest12/8wks.
Findings from the scenario analyses of different resistance test
costs and different first-line cure rates in patients with NS5A
resistance are presented in Figure 3. The probability of cost-
effectiveness and expected INMB are presented for each scenario
at £30 000 willingness-to-pay. In each scenario, the probability of
cost-effectiveness and expected INMB are presented on the ver-
tical axis, with changes in the key parameter outlined on the
horizontal axis. Results were somewhat sensitive to increases in
the cost of the resistance test (ie, single-gene sequencing test). At
resistance test costs greater than £220 (and assuming an 80%
reduction in drug prices), Test12/8wks was no longer the most
cost-effective strategy (base-case cost was £100); at these costs,
NoTest8wks had the highest probability (56%) of being most cost-
effective. Nevertheless, little difference in the expected INMB
versus NoTest12wks was observed, with both strategies proving
cost-effective. Results were sensitive to variations in the first-line
cure rate in patients with NS5A resistance. At cure rates less than
87.5% over 12 weeks, Test12/8wks was no longer the most cost-
effective strategy (base-case SVR12 was 95.7%), losing out to
NoTest8wks, which had lower overall lifetime costs. Nevertheless,
Test12/8wks remained more cost-effective than NoTest12wks,
returning a positive expected INMB at all SVR rates below the base
case.The results remained generally unchanged when we assumed
the same utilities for HCV-cleared as HCV-infected patients, as
detailed in Appendix 5.
Finally, Figure 4 presents the results from the 2-way probabi-
listic sensitivity analysis that compared differential percentage
reductions in the cost of first-line treatment and retreatment. The
percentage reduction in the cost of first-line treatment is pre-
sented on the y-axis, with the percentage reduction in the cost of
retreatment depicted on the x-axis. The grid reports the proba-
bility that any strategy is the most cost-effective strategy for a
given price combination (ie, percentage reduction). When first-
line treatment drug prices were low (,£20k) and retreatment
drug costs were high (.£22k), the findings favored Test12/8wks.
Conversely, when retreatment drug costs were low (,£22k) and
first-line treatment drug prices were high (.£20k), the results
favored NoTest8wks. When both first-line treatment and retreat-
ment drug costs were less than ,£20k, the results largely favored
Test12/8wks; however, some uncertainty was observed. Increased
percentage reductions in the cost of retreatment sometimes
favored NoTest8wks, as the strategy had a greater number of pa-
tients requiring retreatment. Hence, the strategy benefitted from
reductions in the cost of the salvage regimen. For no given price
combination was NoTest12wks cost-effective.Discussion
Strengths and Limitations
This is the first study to consider the cost-effectiveness of
testing for resistance to NS5A inhibitor in the United Kingdom.
Furthermore, it is the first study to consider it in the context of
stratifying patients to a shortened 8-week treatment duration in
the absence of NS5A polymorphisms. Previous analyses that
considered baseline testing used longer treatment durations, with
Figure 1. One-way sensitivity analysis of NoTest8wks versus NoTest12wks.
*Assumes 80% reduction in drug costs. NoTest12wks indicates standard 12-week treatment duration (with no testing); NoTest8wks, shortened 8-week
treatment duration (with no testing).
186 VALUE IN HEALTH FEBRUARY 2020patients stratified to a 12-week treatment duration in the absence
of NS5A polymorphisms or 16-week treatment duration in the
presence of NS5A polymorphisms, which is more costly and often
of limited clinical benefit.8 Elbasha and colleagues7 also consid-
ered longer durations; however, the authors investigated the cost-
effectiveness of baseline testing in patients who generally require
extended treatment durations because of severe liver fibrosis or
compensated cirrhosis. In GT1 noncirrhotic TN patients, an 8-
week treatment duration is effective5,9 and cost-effective across
a range of DAAs currently approved for use in the United
Kingdom.10 The shortened treatment duration is becoming more
commonplace, with newer regimens now being administered over
8 weeks.11 Nevertheless, our findings suggest that where signifi-
cant price reductions are available, the nonstratified treatment
approach (NoTest8wks) is less favorable than the stratified/
personalized treatment approach (Test12/8wks) considered here.
We used LDV/SOF as our first-line treatment regimen because
of the availability of data on the effectiveness of the regimen over
a shortened 8-week treatment duration and by NS5A resistance.
Our findings may be generalizable to newer regimens, such as
ELB/GZR and SOF/VEL, which carry similar costs and health utili-
ties, if the cure rates produced by these regimens are comparable
with LDV/SOF over the same treatment durations and by NS5A
resistance. At present, these regimens are licensed for 12 weeks inthe United Kingdom,6,29 so there is limited evidence on the
effectiveness of these regimens over the shortened treatment
duration and by NS5A resistance. It is likely, however, that com-
parable cure rates may be achieved with the newer regimens,
suggesting our findings are not limited to use of LDV/SOF but can
be applied to other commonly used DAAs currently licensed for 12
weeks. Whether resistance testing is preferable to an 8- or 12-
week treatment duration largely depends on the price combina-
tion of first- and second-line DAA therapy, which we report in full
in this analysis.
There are limitations associated with this work. Although we
used rich data from Sarrazin and colleagues5 on the prevalence
of NS5A resistance among genotype 1 noncirrhotic TN patients,
we acknowledge these data, which were derived from clinical
trials in Europe and the United States, may not reflect the
prevalence of NS5A resistance in the UK population. We com-
bined information on subtypes GT1a and GT1b in our analysis
and assumed the same outcomes (SVR) in patients with NS5A
polymorphisms across the 2 subtypes. It is possible that out-
comes differ between GT1a and GT1b. Sarrazin et al5 observed a
slightly higher SVR in GT1a than GT1b TN patients; however, the
authors could discern no significant difference between the 2
subtypes. We grouped NS5A RASs (ie, Q30H, Q30G, Q30R, etc) in
our analysis, as in Sarrazin et al,5 but further stratification by
Figure 2. One-way sensitivity analysis of Test12/8wks versus NoTest12wks.
*Assumes 80% reduction in drug costs. NoTest12wks indicates standard 12-week treatment duration (with no testing); Test12/8wks, baseline testing with 12-
week treatment duration if NS5A resistant, 8 weeks otherwise.
ECONOMIC EVALUATION 187RASs could be undertaken. Nevertheless, such an analysis re-
quires a detailed breakdown of SVR by each polymorphism,
which has yet to be undertaken or made available, to the best of
our knowledge. We explored the cost-effectiveness of testing for
NS5A resistance, but other resistance variants exist (eg, NS5B
and NS3) and could be explored with further research. Never-
theless, Sarrazin et al5 found no association between these var-
iants and treatment outcomes. The Markov model assumed
yearly cycles to reflect the known natural disease history of HCV.
A limitation of using yearly cycles is that the model could not
capture the probability of 2 events occurring in the same year,
such as progression to compensated cirrhosis and hepatocellular
carcinoma. The probability of these events occurring, however,
particularly hepatocellular carcinoma, is low in this population
of noncirrhotic patients, and few patients progress to compen-
sated cirrhosis overall because of the highly efficacious nature of
first- and second-line treatment. Shorter cycles could be adopted
but are unlikely to detect meaningful differences between the
strategies, which had similarly low numbers of clinical events.
The model assumed that patients who failed first-line therapy
were quickly retreated and that there was no loss to follow-up.
Nevertheless, in practice, second-line therapy may be delayed,
leading to a potential loss to follow-up, particularly in prob-
lematic populations, such as chaotic drug users or prisoninmates serving short sentences. Future research should explore
the potential cost-effectiveness of baseline testing in these spe-
cific populations.
Implications for Practice
The clinical and practical benefits of stratifying patients to
different treatment durations based on the presence of NS5A
polymorphisms are clear. Patients’ chances of viral eradication are
increased, and for any patient failing first-line therapy, their future
likelihood of viral eradication with retreatment is high, with
success rates in excess of 96% observed, even in patients with
NS5A resistance.14 Treating most patients over a shortened 8-
week treatment duration provides an opportunity not only to
address the burden of high treatment costs that arise with longer
treatment durations but also better deliver care to more patients
quicker. This may be particularly relevant in health systems where
the cost of HCV drugs remains a barrier to wider access. Aside
from cost, the main negative issue related to resistance testing is
the time taken and degree of specialization needed to receive and
interpret results. In some settings, this may present an obstacle to
increasing access to treatment, particularly in high-burden/low-
income settings where infrastructure is limited. In the United
Kingdom, testing for resistance to NS5A inhibitors at baseline is
Figure 3. Results on the (a) probability of cost-effectiveness and (b) expected incremental net monetary benefit versus 12 weeks (no
testing) of various scenario analyses, at £30 000 willingness-to-pay: (i) different resistance test costs (assuming 80% reduction in drug
costs) and (ii) different first-line cure rates in patients with NS5A resistance (assuming 80% reduction in drug costs).
NoTest12wks indicates standard 12-week treatment duration (with no testing); NoTest8wks, shortened 8-week treatment duration (with no testing); Test12/
8wks, baseline testing with 12-week treatment duration if NS5A resistant, 8 weeks otherwise.
188 VALUE IN HEALTH FEBRUARY 2020routinely recommended for patients receiving ELB/GZR, so the
infrastructure exists to expand this to all patients.
Testing for resistance to NS5A inhibitor-containing regimens in
GT1 noncirrhotic TN patients in the United Kingdom is cost-
effective as drug prices fall to lower levels. The personalized
approach to treatment offers significant clinical and practical
benefits: the patient’s chances of viral eradication are maximized,
fewer patients progress to more advanced stages of liver disease,
and more patients can be effectively treated quicker.Conclusions
We investigated the cost-effectiveness of testing for resistance
to NS5A inhibitor-containing regimens at baseline, with treatment
duration optimized according to the presence of NS5A poly-
morphisms, in GT1 noncirrhotic TN patients in the United
Kingdom. The cost of treatment proved the key driver of cost-
effectiveness in this study. Using cost-effectiveness thresholds of
£20 000 to £30 000, we found that baseline testing (Test12/8wks)
has a low probability (26%-31%) of being cost-effective when the
cost of first-line treatment and retreatment are high (w£40 000
and w£44 000 per patient over 12 weeks, respectively). At theseprices, a shortened 8-week treatment duration (NoTest8wks) has
the highest probability (69%-74%) of being most cost-effective.
Nevertheless, when drug prices are reduced by 80%, the results
are reversed at the higher £30 000 cost-effectiveness threshold. In
fact, we found baseline testing has the highest probability of being
most cost-effective when first-line treatment drug prices are low
(,£20 000) and retreatment drug prices are high (.£22 000).
When both first-line treatment and retreatment drug prices are
low (,£20 000), baseline testing largely remains the most cost-
effective strategy; however, shortened 8-week treatment is
sometimes favored, as the strategy benefits more from increased
price reductions in the cost of retreatment because of greater
numbers requiring the salvage regimen. Although the cost of first-
line treatment and retreatment remains unknown, we present the
complete range of price combinations that could exist and report
the combinations at which the proposed strategies have the
highest probability of being most cost-effective, provided society
is willing to pay £30 000 per QALY gained.
The results are somewhat sensitive to increases in the cost of
the resistance test. Baseline testing is most cost-effective up to a
threshold of £220 per resistance test (assuming an 80% reduction
in drug prices). Single-gene sequencing is expected to cost in the
region of £50 to £150 in the United Kingdom, suggesting the
Figure 4. Results of the probability of cost-effectiveness of differential percentage reductions in the cost of first-line treatment and
retreatment, at £30 000 willingness-to-pay.
NoTest12wks indicates standard 12-week treatment duration (with no testing); NoTest8wks, shortened 8-week treatment duration (with no testing); Test12/
8wks, baseline testing with 12-week treatment duration if NS5A resistant, 8 weeks otherwise. Under no scenario did NoTest12wks have the highest
probability of being most cost-effective.
ECONOMIC EVALUATION 189strategy is cost-effective at the lower drug tariffs. The strategy is
also sensitive to variations in SVR12 in patients with NS5A resis-
tance treated over 12 weeks (assuming the same 80% reduction in
drug prices). At cure rates less than 87.5%, the strategy is no longer
the most cost-effective option. Nevertheless, DAAs rarely produce
cure rates less than 90% over a 12-week treatment duration,
suggesting that this threshold is unlikely to be breached. Overall,
we found that the standard 12-week treatment (NoTest12wks) is
not cost-effective versus either baseline testing or a shortened
8-week treatment.
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